Evidence method
Level · gp.fundamentals.capex_revenue_ratio
6.86% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
IBRX · Jun 30, 2026
ImmunityBio, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001326110-26-000079General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-129.77% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
93.91% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
3.79% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
99.42% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-120.41% · CORE · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
16.62% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History9 statesHistory building
Period transition
What moved in the state?
- Previous
- 4.02%
- Current
- 6.86%
- Delta
- 2.84%
- Previous
- -170.47%
- Current
- -129.77%
- Delta
- 40.70%
- Previous
- 167.64%
- Current
- 93.91%
- Delta
- -73.73%
- Previous
- 1.24%
- Current
- 3.79%
- Delta
- 2.55%
- Previous
- 99.46%
- Current
- 99.42%
- Delta
- -0.04%
- Previous
- -157.88%
- Current
- -120.41%
- Delta
- 37.47%
- Previous
- 18.48%
- Current
- 16.62%
- Delta
- -1.86%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Compared To · Biological Products, (No Diagnostic Substances) peers →Has State · ImmunityBio, Inc. →Transitioned To · IBRX Fundamental State →Transitioned To · IBRX CAPEX_INTENSITY_INCREASED →Transitioned To · IBRX CASH_GENERATION_INCREASED →Transitioned To · IBRX GROWTH_DECREASED →Transitioned To · IBRX INVENTORY_PRESSURE_INCREASED →Transitioned To · IBRX MARGIN_DECREASED →Transitioned To · IBRX PROFITABILITY_INCREASED →Transitioned To · IBRX SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.